Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET
Company Participants
Jenna Cohen - Senior Director and Head of Investor Relations
Kate Haviland - Chief Executive Officer
Christy Rossi - Chief Operating Officer
Philina Lee - Chief Commercial Officer
Becker Hewes - MD, Chief Medical Officer
Mike Landsittel - Chief Financial Officer
Conference Call Participants
Marc Frahm - Cowen
Dane Leone - Raymond James
Elizabeth - Goldman Sachs
Reni Benjamin - JMP Securities
Brad Canino - Stifel
Yige Guo - Guggenheim Securities
Andrew Berens - SVB Securities
Mike Ulz - Morgan Stanley
David Lebowitz - Citi
Eun Yang - Jefferies
Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine-assisted output provided is partly edited and is designed as a guide.
Operator
00:03 Good morning. My name is Juan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicine's First Quarter 2022 Financial Results Conference Call. [Operator Instructions] After the speakers’ remarks there will be a question-and-answer session. [Operator Instructions] Thank you.
00:37 I would now like to turn the call over to your host, Jenna Cohen from Blueprint Medicines. Jenna, you may begin your conference.
Jenna Cohen
00:46 Thank you, Juan. Good morning, everyone, and welcome to Blueprint Medicines First Quarter 2022 Financial and Operating Results Conference Call. This morning we issued a press release, which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors Section of our website at www.blueprintmedicines.com.
01:11 Today on our call Kate Haviland, our Chief Executive Officer, will discuss Blueprint Medicines pillars for growth through 2023. Christy Rossi, our Chief Operating Officer, will provide an advanced SM launch update. Philina Lee, our Chief Commercial Officer, will provide a non-advanced SM market opportunity update. Becker Hewes, Chief Medical Officer, will review our recent clinical progress and highlight upcoming milestones across our growing portfolio; and Mike Landsittel, our Chief Financial Officer, will review our first quarter 2022 financial results. Percy Carter, our Chief Scientific Officer, is also joining our call and will be available for Q&A.
01:54 Before we get started, I would like to remind everyone that statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of SEC filings. In addition, any forward-looking statement made on this call represents our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statement.